$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

$alxo Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000156459022007364 Filed on February 28, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.674M	$7.578M	$23.39M
YoY Change	76.01%	33.42%	57.9%
% of Gross Profit
Research & Development	$17.07M	$20.89M	$60.17M
YoY Change	73.35%	72.11%	107.76%
% of Gross Profit
Depreciation & Amortization	$58.00K	$34.00K	$51.00K
YoY Change	1060.0%		-74.75%
% of Gross Profit
Operating Expenses	$24.75M	$28.47M	$83.56M
YoY Change	74.18%	59.73%	86.32%
Operating Profit	-$24.75M		-$83.56M
YoY Change	74.18%		91.36%
Interest Expense	$225.0K	-$3.000K	-$13.00K
YoY Change	800.0%	-98.0%	-98.4%
% of Operating Profit
Other Income/Expense, Net	-$11.00K	$16.00K	$84.00K
YoY Change	450.0%	60.0%	-120.79%
Pretax Income	-$24.53M	-$28.46M	-$83.48M
YoY Change	72.95%	53.09%	83.49%
Income Tax		-$21.00K	-$21.00K
% Of Pretax Income
Net Earnings	-$24.53M	-$28.44M	-$83.46M
YoY Change	72.95%	51.51%	82.47%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.60		-$2.07
Diluted Earnings Per Share	-$604.0K	-$701.7K	-$2.071M
COMMON SHARES
Basic Shares Outstanding	40.63M	40.50M	40.31M
Diluted Shares Outstanding	40.62M		40.31M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$316.6M	$363.7M	$363.7M
YoY Change	-26.36%	-16.24%	-16.24%
Cash & Equivalents	$159.1M	$363.7M	$363.7M
Short-Term Investments	$157.5M
Other Short-Term Assets	$4.929M	$3.352M	$3.352M
YoY Change	97.16%	86.22%	86.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$321.5M	$367.0M	$367.0M
YoY Change	-25.63%	-15.82%	-15.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.338M	$897.0K	$3.397M
YoY Change	2746.81%	1625.0%	3297.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.11M
YoY Change
Other Assets	$15.70M	$12.27M	$9.767M
YoY Change	2829.85%	122570.0%
Total Long-Term Assets	$42.15M	$13.16M	$13.16M
YoY Change	7130.02%	21132.26%	13064.0%
TOTAL ASSETS
Total Short-Term Assets	$321.5M	$367.0M	$367.0M
Total Long-Term Assets	$42.15M	$13.16M	$13.16M
Total Assets	$363.7M	$380.2M	$380.2M
YoY Change	-15.99%	-12.81%	-12.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.133M	$3.764M	$3.764M
YoY Change	-30.16%	94000.0%
Accrued Expenses	$9.746M	$11.10M	$11.10M
YoY Change	260.96%	85.03%	85.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$429.0K	$429.0K	$429.0K
YoY Change	329.0%
Total Short-Term Liabilities	$15.31M	$15.30M	$15.30M
YoY Change	8.34%	146.53%	146.69%
LONG-TERM LIABILITIES
Long-Term Debt	$175.0K	$280.0K	$280.0K
YoY Change	75.0%
Other Long-Term Liabilities	$4.772M	$1.839M	$1.559M
YoY Change	1506.73%	36680.0%
Total Long-Term Liabilities	$4.772M	$1.839M	$1.839M
YoY Change	1506.73%	36680.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.31M	$15.30M	$15.30M
Total Long-Term Liabilities	$4.772M	$1.839M	$1.839M
Total Liabilities	$20.08M	$17.13M	$17.13M
YoY Change	39.19%	175.95%	176.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$226.5M	-$202.0M
YoY Change	70.69%	70.42%
Common Stock	$570.7M	$565.0M
YoY Change	3.54%	3.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$343.6M	$363.0M	$363.0M
YoY Change
Total Liabilities & Shareholders Equity	$363.7M	$380.2M	$380.2M
YoY Change	-15.99%	-12.81%	-12.82%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$24.53M	-$28.44M	-$83.46M
YoY Change	72.95%	51.51%	82.47%
Depreciation, Depletion And Amortization	$58.00K	$34.00K	$51.00K
YoY Change	1060.0%		-74.75%
Cash From Operating Activities	-$20.67M	-$17.49M	-$68.10M
YoY Change	302.61%	28.4%	77.86%
INVESTING ACTIVITIES
Capital Expenditures	$589.0K	-$4.518M	$666.0K
YoY Change	8314.29%	45080.0%	2048.39%
Acquisitions
YoY Change
Other Investing Activities	-$183.3M
YoY Change
Cash From Investing Activities	-$183.9M	-$4.518M	-$4.923M
YoY Change	2627342.86%	45080.0%	-907.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	80.00K	524.0K	2.472M
YoY Change	-89.72%	-99.72%	-99.47%
NET CHANGE
Cash From Operating Activities	-20.67M	-17.49M	-68.10M
Cash From Investing Activities	-183.9M	-4.518M	-4.923M
Cash From Financing Activities	80.00K	524.0K	2.472M
Net Change In Cash	-204.5M	-21.48M	-70.55M
YoY Change	4586.41%	-112.29%	-116.59%
FREE CASH FLOW
Cash From Operating Activities	-$20.67M	-$17.49M	-$68.10M
Capital Expenditures	$589.0K	-$4.518M	$666.0K
Free Cash Flow	-$21.26M	-$12.97M	-$68.77M
YoY Change	313.52%	-4.7%	79.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19243000
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.151961827
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	548327000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118522000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	429845000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	436054000
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	us-gaap	Liabilities Liabilities	6209000
CY2020	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	5202000
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity File Number EntityFileNumber	001-39386
CY2021	dei	Entity Registrant Name EntityRegistrantName	ALX ONCOLOGY HOLDINGS INC
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	323 Allerton Avenue
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3352000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	363667000
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-0642577
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2021	dei	City Area Code CityAreaCode	650
CY2021	dei	Local Phone Number LocalPhoneNumber	466-7125
CY2021	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021	dei	Trading Symbol TradingSymbol	ALXO
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q4	us-gaap	Assets Current AssetsCurrent	435992000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12267000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10000
CY2020Q4	us-gaap	Assets Assets	436054000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1773000
CY2021Q4	us-gaap	Liabilities Liabilities	17134000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52000
CY2021Q4	us-gaap	Assets Assets	380183000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1839000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40630885
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherAssets
CY2021Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PrepaidExpenseAndOtherAssets
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	false
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021Q2	dei	Entity Public Float EntityPublicFloat	960000000.0
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.151961827
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	alxo	Type Of Revenue Description TypeOfRevenueDescription	Related-party
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y3M18D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M9D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M10D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M28D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.003
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.017
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.797
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.787
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.752
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.008
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.021
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.869
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.890
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.805
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	San Francisco, California
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	434219000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	367019000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3764000
CY2020Q4	alxo	Payable And Accrued Liabilities Due To Related Party Current PayableAndAccruedLiabilitiesDueToRelatedPartyCurrent	72000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6128000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6204000
CY2021Q4	alxo	Payable And Accrued Liabilities Due To Related Party Current PayableAndAccruedLiabilitiesDueToRelatedPartyCurrent	1630000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9901000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15295000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40587067
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40587067
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	564993000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201985000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	363049000
CY2020	us-gaap	Operating Expenses OperatingExpenses	44845000
CY2021	us-gaap	Operating Expenses OperatingExpenses	83555000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-83555000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-19183000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-13000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-404000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23385000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-43663000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-811000
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-21000
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45499000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19243000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	429845000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14809000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28961000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19209000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-19243000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23271000
CY2021	us-gaap	Profit Loss ProfitLoss	-83463000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Profit Loss ProfitLoss	-45740000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39844522
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39844522
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	40000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	380183000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1182000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4796000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60170000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16306000
CY2020	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1075000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	84000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83484000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	5202000
CY2019	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4028000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83463000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50942000
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.07
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-2.76
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-7.56
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40308050
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18485343
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3076461
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-51778000
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000
CY2019	alxo	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	75000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	297000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-70639000
CY2020	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount	-1019000
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	175043000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	364400000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	299000
CY2020	alxo	Stock Issued During Period Value Vesting Of Early Exercised Stock Options StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions	27000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5436000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2551000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	202000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13914000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	363049000
CY2019	us-gaap	Profit Loss ProfitLoss	-19243000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	202000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	429000
CY2021	alxo	Non Cash Lease Costs NonCashLeaseCosts	685000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4739000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	13914000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	5436000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	297000
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	421000
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11000
CY2020	alxo	Changes In Fair Value Of Compound Derivative Liability And Warrants ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants	650000
CY2020	alxo	Gain On Assignment Of Lease GainOnAssignmentOfLease	126000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-621000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3313000
CY2019	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	4360000
CY2019	us-gaap	Operating Expenses OperatingExpenses	23979000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	353000
CY2021	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4257000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	425202000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	755000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	434219000
CY2020	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-536000
CY2019	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-396000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1662000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1514000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-744000
CY2021	alxo	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	9682000
CY2020	alxo	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	10000
CY2019	alxo	Increase Decrease In Other Assets IncreaseDecreaseInOtherAssets	-7000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3290000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3744000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2976000
CY2021	alxo	Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent	1419000
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	3306000
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	4983000
CY2019	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	134000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-698000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68101000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38289000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14249000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	666000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000
CY2020	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	641000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4923000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	610000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-353000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	368256000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3848000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2551000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	299000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	202000
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	104680000
CY2019	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	9430000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	281000
CY2019	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	5917000
CY2020	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	6506000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2472000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	462881000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15357000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-70552000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9017000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8262000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	363667000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	434219000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9017000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	11000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	427000
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	274000
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	47000
CY2020	alxo	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	27000
CY2019	alxo	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	75000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	237000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	7000
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	482000
CY2019	alxo	Noncash Or Part Noncash Debt Issuance Costs In Accounts Payable NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable	95000
CY2020	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	175043000
CY2020	alxo	Non Cash Accumulated Dividend On Convertible Preferred Stock NonCashAccumulatedDividendOnConvertiblePreferredStock	3000
CY2021	alxo	Right Of Use Asset Acquired Under Operating Leases RightOfUseAssetAcquiredUnderOperatingLeases	1780000
CY2021	alxo	Right Of Use Asset Acquired Under Finance Leases RightOfUseAssetAcquiredUnderFinanceLeases	776000
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have also been made within the consolidated balance sheet as of December 31, 2020 to conform to the current year presentation. The Company reclassified approximately $0.1 million out of accrued expenses and other current liabilities into payable and accrued liabilities due to related-party. Total current liabilities as of December 31, 2020 did not change as a result of these reclassifications. </p>
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 8, 2020, the Company’s board of directors approved an amendment to the Company’s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock.
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company’s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	960000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	77000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	25000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	52000
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	200000
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12267000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10000
CY2021Q4	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	4125000
CY2020Q4	alxo	Accrued Clinical And Non Clinical Costs Current AccruedClinicalAndNonClinicalCostsCurrent	1401000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3294000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1974000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	790000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	300000
CY2021Q4	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	693000
CY2020Q4	alxo	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	2123000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	429000
CY2021Q4	alxo	Operating Lease Liability With Related Party Current OperatingLeaseLiabilityWithRelatedPartyCurrent	313000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	257000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	151000
CY2020Q4	alxo	Accrued Federal Income Tax AccruedFederalIncomeTax	179000
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9901000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	6128000
CY2021	us-gaap	Lessee Finance Lease Option To Extend LesseeFinanceLeaseOptionToExtend	no
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1800000
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	700000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	519000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due In Next Rolling Twelve Months FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths	432000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	482000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due In Rolling Year Two FinanceLeaseLiabilityPaymentsDueInRollingYearTwo	288000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	433000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	446000
CY2021Q4	alxo	Operating Lease Liabilities Payments Due Thereafter OperatingLeaseLiabilitiesPaymentsDueThereafter	301000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2181000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	720000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	166000
CY2021	alxo	Variable Lease Cost And Other Net VariableLeaseCostAndOtherNet	84000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	369000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	13000
CY2021	us-gaap	Lease Cost LeaseCost	826000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3143797
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.88
CY2021Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	11000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2015000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	709000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	457000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	429000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1558000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	280000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2015000
CY2021Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	709000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.035
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.017
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1875000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	360000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	243000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	11000
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	281000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1780000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	776000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	140000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two And Three Years OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears	206000
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	346000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	48625000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	8000
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40587067
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39844522
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	42.29
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.74
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.27
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-4031000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-5000
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	60000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	2131000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	512000
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9342434
CY2020	alxo	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised	63
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2021	alxo	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised	0
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	297000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	68700000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5325000
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2861000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	76000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2835445
CY2021	alxo	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized	1593781
CY2021	alxo	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted	1447470
CY2021	alxo	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Canceled ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled	426142
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3407898
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4857308
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.94
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	375270000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1432395
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	60.21
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	734922
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.47
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	426142
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.62
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5128639
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.91
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	49745000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	48100000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4400000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13914000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5436000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-30565000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-9457000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	813000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-52919000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-36042000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-20022000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-83484000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45499000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19209000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-21000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	239000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	33000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	241000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	34000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-17532000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9555000
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4034000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-105000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3098000
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	861000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11476000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5710000
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3733000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	172000
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	321000
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	75000
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	11032000
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	7380000
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3886000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	1098000
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-950000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	241000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	34000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15407000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7283000
CY2021Q4	alxo	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	529000
CY2020Q4	alxo	Deferred Tax Assets Accrued Expenses DeferredTaxAssetsAccruedExpenses	383000
CY2021Q4	alxo	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	1530000
CY2020Q4	alxo	Deferred Tax Assets Stock Options DeferredTaxAssetsStockOptions	696000
CY2021Q4	alxo	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	542000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	23349000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11299000
CY2021Q4	alxo	Deferred Tax Liabilities Property Plant And Equipment1 DeferredTaxLiabilitiesPropertyPlantAndEquipment1	73000
CY2020Q4	alxo	Deferred Tax Liabilities Property Plant And Equipment1 DeferredTaxLiabilitiesPropertyPlantAndEquipment1	11000
CY2019	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	494000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	240000
CY2021Q4	alxo	Deferred Tax Liabilities Lease Right Of Use Assets DeferredTaxLiabilitiesLeaseRightOfUseAssets	541000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	614000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22735000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11288000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11400000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4600000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1200000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	800000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	700000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	842000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	692000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	418000
CY2021	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-69000
CY2020	alxo	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-64000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	272000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	50000
CY2020	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	26000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1217000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	842000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	692000
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-83463000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-45740000
CY2021Q4	alxo	Finance Lease Liability To Be Paid Year Two And Three FinanceLeaseLiabilityToBePaidYearTwoAndThree	288000
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	21211000
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	17578000
CY2021Q4	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	3550000
CY2019	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	4028000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-83463000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50942000
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23271000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40308050
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18485343
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3076461
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.07
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.76
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.56
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5143714
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4857371
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11592869
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2181000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	519000
CY2021Q4	alxo	Lessee Operating Lease Liability To Be Paid Year Two And Three LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree	915000
CY2021Q4	alxo	Lessee Operating Lease Liability To Be Paid Year Four And Five LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive	747000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	720000
CY2021Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	432000
CY2021Q4	us-gaap	Purchase Obligation Due In Fourth And Fifth Year PurchaseObligationDueInFourthAndFifthYear	83000
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	24112000
CY2021Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	18529000
CY2021Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	4753000
CY2021Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	830000
CY2021	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001564590-22-007364-index-headers.html	Edgar Link	pending
0001564590-22-007364-index.html	Edgar Link	pending
0001564590-22-007364.txt	Edgar Link	pending
0001564590-22-007364-xbrl.zip	Edgar Link	pending
alxo-10k_20211231.htm	Edgar Link	pending
alxo-10k_20211231_htm.xml	Edgar Link	completed
alxo-20211231.xsd	Edgar Link	pending
alxo-20211231_cal.xml	Edgar Link	unprocessable
alxo-20211231_def.xml	Edgar Link	unprocessable
alxo-20211231_lab.xml	Edgar Link	unprocessable
alxo-20211231_pre.xml	Edgar Link	unprocessable
alxo-ex106_1098.htm	Edgar Link	pending
alxo-ex211_1662.htm	Edgar Link	pending
alxo-ex231_9.htm	Edgar Link	pending
alxo-ex311_10.htm	Edgar Link	pending
alxo-ex312_6.htm	Edgar Link	pending
alxo-ex321_7.htm	Edgar Link	pending
alxo-ex322_8.htm	Edgar Link	pending
alxo-ex43_11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g4tgzu1brivt000001.jpg	Edgar Link	pending
g4tgzu1brivt000002.jpg	Edgar Link	pending
g4tgzu1brivt000003.jpg	Edgar Link	pending
g4tgzu1brivt000004.jpg	Edgar Link	pending
g4tgzu1brivt000005.jpg	Edgar Link	pending
g4tgzu1brivt000006.jpg	Edgar Link	pending
g4tgzu1brivt000007.jpg	Edgar Link	pending
g4tgzu1brivt000008.jpg	Edgar Link	pending
g4tgzu1brivt000009.jpg	Edgar Link	pending
g4tgzu1brivt000010.jpg	Edgar Link	pending
g4tgzu1brivt000011.jpg	Edgar Link	pending
g4tgzu1brivt000012.jpg	Edgar Link	pending
g4tgzu1brivt000013.jpg	Edgar Link	pending
g4tgzu1brivt000014.jpg	Edgar Link	pending
g4tgzu1brivt000015.jpg	Edgar Link	pending
g4tgzu1brivt000016.jpg	Edgar Link	pending
g4tgzu1brivt000017.jpg	Edgar Link	pending
g4tgzu1brivt000018.jpg	Edgar Link	pending
g4tgzu1brivt000019.jpg	Edgar Link	pending
g4tgzu1brivt000020.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo

2022 Q1 Form 10-K Financial Statement

#000156459022007364 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO ALX ONCOLOGY HOLDINGS INC Stock $alxo

2022 Q1 Form 10-K Financial Statement

#000156459022007364 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALXO
ALX ONCOLOGY HOLDINGS INC Stock $alxo